Empowered Funds LLC Has $34.79 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• Empowered Funds LLC increased its stake in Johnson & Johnson by 10.3% during Q1, now holding a total of 209,778 shares valued at $34.79 million.
• Other hedge funds have also raised their positions, with Logan Capital Management boosting its stake by 119.1%, adding an additional 57,549 shares.
• Johnson & Johnson recently posted $2.77 EPS for the quarter, beating estimates, and has set its FY 2025 guidance at 10.800-10.900 EPS.

Empowered Funds LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 209,778 shares of the company's stock after buying an additional 19,540 shares during the period. Johnson & Johnson accounts for 0.5% of Empowered Funds LLC's holdings, making the stock its 21st largest holding. Empowered Funds LLC's holdings in Johnson & Johnson were worth $34,790,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Logan Capital Management Inc. boosted its position in Johnson & Johnson by 119.1% in the first quarter. Logan Capital Management Inc. now owns 105,885 shares of the company's stock valued at $17,560,000 after buying an additional 57,549 shares in the last quarter. AAF Wealth Management LLC boosted its position in Johnson & Johnson by 6.3% in the first quarter. AAF Wealth Management LLC now owns 1,810 shares of the company's stock valued at $300,000 after buying an additional 107 shares in the last quarter. HFM Investment Advisors LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $836,000. MBB Public Markets I LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $325,000. Finally, Adalta Capital Management LLC boosted its position in Johnson & Johnson by 0.4% in the first quarter. Adalta Capital Management LLC now owns 18,344 shares of the company's stock valued at $3,042,000 after buying an additional 73 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $178.30 on Tuesday. The firm has a market cap of $429.40 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company's fifty day simple moving average is $169.09 and its 200 day simple moving average is $160.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, UBS Group lifted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.